Shoulder Innovations Inc (SI) is a medical device company that develops and commercializes implant systems for shoulder arthroplasty procedures. Revenue is generated through the transactional sale of shoulder implants and supporting surgical technologies to hospitals and surgeons. The company competes against larger orthopedic device manufacturers that have greater sales resources, broader product lines, and more established distribution networks. SI's core product is the InSet Glenoid, a glenoid implant system supported by approximately nine years of published clinical data, including four studies in the Journal of Shoulder and Elbow Surgery. The company also uses ProVoyance, a preoperative planning technology adopted beginning in 2021, and has developed fracture-specific, revision, and metal-hypersensitivity implant solutions. SI reported a net loss of $40,359 thousand for the year ended December 31, 2025, and used $28,612 thousand in cash from operating activities in that same period. The company is pre-profitability, relies on third-party manufacturers and independent distributors, and is building an international commercial presence. Robert Ball serves as Chief Executive Officer and Executive Chairman and is a co-founder of Genesis Innovation Group, Inc.

Revenue model

Transactional sales of shoulder implant systems and supporting surgical technologies to hospitals and surgeons. No subscription or royalty revenue model is disclosed in the filing excerpts.

Products and services

InSet Glenoid implant system, ProVoyance preoperative planning technology (adopted 2021), fracture-specific implant system, revision solution, and implants for patients with metal-hypersensitivity.

Customers and end markets

Surgeons and hospitals performing shoulder arthroplasty procedures. End market is orthopedic surgical care for glenohumeral joint conditions including osteoarthritis, inflammatory arthritis, and shoulder arthritis with glenoid bone deficiency. Adjacent markets identified in the filing include sports medicine and trauma.

Value-chain role

Medical device developer and commercializer. Relies on third-party manufacturers and suppliers for production. Uses independent distributors for sales and is expanding direct international operations.

Geographic exposure

Primarily domestic with an expanding international presence. Specific country or regional revenue mix is not disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-10

Industry: Surgical & Medical Instruments & Apparatus